Literature DB >> 19265479

Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.

Wei Jiang1, Michael M Lederman, Peter Hunt, Scott F Sieg, Kathryn Haley, Benigno Rodriguez, Alan Landay, Jeffrey Martin, Elizabeth Sinclair, Ava I Asher, Steven G Deeks, Daniel C Douek, Jason M Brenchley.   

Abstract

The significance of elevated plasma levels of bacterial lipopolysaccharide (LPS) in persons with chronic HIV infection remains undefined. We measured LPS levels by use of limulus lysate assay, and DNA sequences encoding bacterial ribosomal 16S RNA (16S rDNA) were assessed by quantitative polymerase chain reactions in plasma samples obtained from 242 donors. Plasma levels of 16S rDNA were significantly higher in human immunodeficiency virus (HIV)-infected subjects than in uninfected subjects, and they correlated with LPS levels. Higher levels of 16S rDNA were associated with higher levels of T cell activation and with lower levels of CD4 T cell restoration during antiretroviral therapy. Antiretroviral therapy reduces but does not fully normalize plasma levels of bacterial 16S rDNA, an index of microbial translocation from the gastrointestinal tract. High levels of 16S rDNA during therapy are strongly associated with reduced increases in the CD4(+) T lymphocyte count, irrespective of plasma HIV RNA levels. These findings are consistent with the importance of microbial translocation in immunodeficiency and T cell homeostasis in chronic HIV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265479      PMCID: PMC2728622          DOI: 10.1086/597476

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  A study of endotoxemia in ulcerative colitis and Crohn's disease. I. Clinical study.

Authors:  K Aoki
Journal:  Acta Med Okayama       Date:  1978-06       Impact factor: 0.892

2.  Apoptosis induced in CD4+ cells expressing gp160 of human immunodeficiency virus type 1.

Authors:  Y Y Lu; Y Koga; K Tanaka; M Sasaki; G Kimura; K Nomoto
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

3.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

Authors:  N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

4.  Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement.

Authors:  Scott F Sieg; Benigno Rodriguez; Robert Asaad; Wei Jiang; Douglas A Bazdar; Michael M Lederman
Journal:  J Infect Dis       Date:  2005-05-26       Impact factor: 5.226

5.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

Authors:  J V Giorgi; L E Hultin; J A McKeating; T D Johnson; B Owens; L P Jacobson; R Shih; J Lewis; D J Wiley; J P Phair; S M Wolinsky; R Detels
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

6.  CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Authors:  Gilbert R Kaufmann; Luc Perrin; Guiseppe Pantaleo; Milos Opravil; Hansjakob Furrer; Amalio Telenti; Bernard Hirschel; Bruno Ledergerber; Pietro Vernazza; Enos Bernasconi; Martin Rickenbach; Matthias Egger; Manuel Battegay
Journal:  Arch Intern Med       Date:  2003-10-13

7.  Changes in thymic function with age and during the treatment of HIV infection.

Authors:  D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

8.  Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors:  M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

9.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Authors:  Bruno Ledergerber; Jens D Lundgren; A Sarah Walker; Caroline Sabin; Amy Justice; Peter Reiss; Cristina Mussini; Ferdinand Wit; Antonella d'Arminio Monforte; Rainer Weber; Gregory Fusco; Schlomo Staszewski; Matthew Law; Robert Hogg; Fiona Lampe; M John Gill; Francesco Castelli; Andrew N Phillips
Journal:  Lancet       Date:  2004 Jul 3-9       Impact factor: 79.321

Review 10.  HIV disease: fallout from a mucosal catastrophe?

Authors:  Jason M Brenchley; David A Price; Daniel C Douek
Journal:  Nat Immunol       Date:  2006-03       Impact factor: 25.606

View more
  326 in total

Review 1.  Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells.

Authors:  Julie R Boiko; Lisa Borghesi
Journal:  Cytokine       Date:  2011-11-12       Impact factor: 3.861

Review 2.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

3.  Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Authors:  Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

4.  Laparoscopic Technique for Serial Collection of Liver and Mesenteric Lymph Nodes in Macaques.

Authors:  Alexander S Zevin; Cassie Moats; Drew May; Solomon Wangari; Charlene Miller; Joel Ahrens; Naoto Iwayama; Megan Brown; Debbie Bratt; Nichole R Klatt; Jeremy Smedley
Journal:  J Vis Exp       Date:  2017-05-02       Impact factor: 1.355

5.  HIV-2 infection is associated with preserved GALT homeostasis and epithelial integrity despite ongoing mucosal viral replication.

Authors:  S M Fernandes; A R Pires; P Matoso; C Ferreira; H Nunes-Cabaço; L Correia; E Valadas; J Poças; P Pacheco; H Veiga-Fernandes; R B Foxall; A E Sousa
Journal:  Mucosal Immunol       Date:  2017-05-17       Impact factor: 7.313

6.  The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.

Authors:  Helen Byakwaga; Yap Boum; Yong Huang; Conrad Muzoora; Annet Kembabazi; Sheri D Weiser; John Bennett; Huyen Cao; Jessica E Haberer; Steven G Deeks; David R Bangsberg; Joseph M McCune; Jeffrey N Martin; Peter W Hunt
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

7.  Estrogen decreases tight junction protein ZO-1 expression in human primary gut tissues.

Authors:  Zejun Zhou; Lumin Zhang; Miao Ding; Zhenwu Luo; Shao Yuan; Meena B Bansal; Gary Gilkeson; Ren Lang; Wei Jiang
Journal:  Clin Immunol       Date:  2017-09-01       Impact factor: 3.969

8.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

Review 9.  Nonhuman primate models of human viral infections.

Authors:  Jacob D Estes; Scott W Wong; Jason M Brenchley
Journal:  Nat Rev Immunol       Date:  2018-06       Impact factor: 53.106

Review 10.  Heart-lung interaction via infection.

Authors:  Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.